



Heart Failure: From Subtype to Personalized Medicine

Guest Editor:

Dr. Yuji Nagatomo

Department of Cardiology,
National Defense Medical
College, Tokorozawa, Saitama
359, Japan

Deadline for manuscript
submissions:

10 October 2024


Message from the Guest Editor

Heart failure (HF) is a major social problem that has been increasing in its prevalence worldwide due to a rapidly aging society. Even though recent progress in the understanding of the pathology of HF and certain forms of cardiomyopathies (e.g. amyloidosis, Fabry disease) has enabled the development of novel diagnostic and management strategies, their prognosis has not yet been satisfactory.

Newly recognized cardiovascular disease entities have emerged as new problems. There have been limited therapeutics for heart failure with preserved ejection fraction (HFpEF). Recent advances in cancer therapy have improved life expectancy for cancer patients, but instead survivors often are left suffering from cardiovascular complications such as cancer therapeutics-related cardiac dysfunction (CTRCD). The current devastating COVID-19 outbreak might cause various cardiovascular complications, such as myocarditis and thrombosis, for some affected patients. However, cardioprotective strategies for these emerging diseases have not yet been established.

This Special Issue aims to highlight the current knowledge and future perspectives potentially leading to novel personalized approaches to HF.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer
Institute, Winston-Salem, NC
27103, USA
2. Division of Hematologic
Malignancies and Cellular
Therapy, Duke University,
Durham, NC 27710, USA

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM; ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, ‘omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank: JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/jpm
jpm@mdpi.com
[X@JPM_MDPI](https://twitter.com/JPM_MDPI)